Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Dental, Vision, and Hearing Inclusion in Senior Protection. - 2Taco Bell debuts its Baja Blast pie, and the reactions may surprise you
- 36 Exemplary Mexican Dishes
- 4The last penny was pressed by the U.S. Mint in Philadelphia today. Could the nickel and dime be next?
- 5Find the Advantages of Positive Nurturing: Supporting Cheerful and Sound Kids
- A definitive Manual for Well known Fragrances
- Cheetos and Doritos to launch new versions without artificial dyes
- Revvity says it will exceed 2025 profit forecast range
- Presenting Nintendo's New Pastel Bliss Con Tones for Switch Gamers: 3 Smart Choices
- Reclassifying Achievement: Individual Accounts of Seeking after Interests
- Selena Quintanilla documentary 'Selena y Los Dinos: A Family's Legacy' is coming to Netflix
- RFK Jr. says fewer flu shots for kids may be 'better.' What experts say.
- Manual for Instructive Application for Youngsters
- 6 Nations for Setting up camp
